Anzeige
Meldung des Tages: Mit Graphen gegen jede Abwehr — Die Zukunft der Drohnen ist da

Zymeworks News

Aktie
WKN:  A3DSSN ISIN:  US98985Y1082 US-Symbol:  ZYME Branche:  Biotechnologie Land:  USA
26,62 $
-0,92 $
-3,34%
22,712 € 01.05.26
Depot/Watchlist
Marktkapitalisierung *
1,57 Mrd. €
Streubesitz
-
KGV
-9,04
Index-Zuordnung
-

Zymeworks News

02.09.25 - GlobeNewswire
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
19.08.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
11.08.25 - GlobeNewswire
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
28.07.25 - GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
Second antibody-​drug conjugate (ADC) to progress into clinical development utilizing our proprietary payload and optimized antibody Preclinical results demonstrate strong anti-...
17.07.25 - GlobeNewswire
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Company to participate in investor conferences in July and August
30.05.25 - GlobeNewswire
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-...
22.05.25 - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® ...
21.05.25 - GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, May 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-​stage biotechnology company developing a diverse pipeline of ...
19.05.25 - GlobeNewswire
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »